Abstract:Parkinson’s disease arises from the demise of dopaminergic neurons in the substantia nigra resulting from both environmental and hereditary factors. Drug interventions can solely delay disease progression, but cannot provide a cure. Therefore, cell replacement therapy may represent a promising treatment approach. Although the United States has already employed this technology, independent clinical and preclinical trials are mandatory for its inclusion in Russia. The iPSC technology enables the acquisition of personalized iPSC lines for each patient, nearly eradicating the immune response. While autologous cell therapy is theoretically ideal, the reprogramming of patient cells into iPSCs and subsequent differentiation for each patient incurs time and cost. Alternatively, differentiated derivatives of low immunogenic iPSCs, lacking HLA class I expression, can serve as a substitute. These cells evade the T-cell immune response, but other minor HLAs and cells from the innate immune system, like macrophages and NK cells, could still participate in the immune response’s development, although not as potent as in allogeneic transplantation. While these cell products don’t escape the immune response entirely, they lessen it significantly, potentially enabling the use of less severe immunosuppressive therapy. In this study, a protocol previously established in the cell biology laboratory was used to differentiate iPSCs lacking HLA class I expression and wild-type iPSCs into midbrain dopaminergic neuron precursors. A thorough analysis of the forerunners was performed and demonstrated appropriate patterning. The progenitors were then implanted into the brains of rats with 6-OHDA-induced Parkinsonism and followed for 6 months to compare their in vivo differentiation to standard differentiation in vitro. In addition, the systemic inflammatory response of the animals to the transplantation and the biodistribution of the injected cells were investigated. The literature inadequately addresses the question of which cells, other than dopaminergic neurons, differentiate during in vivo graft differentiation and potentially cause side effects in cell therapy. The literature suggests that only approximately 3% of transplanted cells differentiate into dopaminergic neurons, which is adequate to improve motor function in model animals. We found that a significant proportion of the progenitors differentiate into glial cells. The dynamics of maturation of transplanted neurons was evaluated. Thus, we approached preclinical testing of the cell product after having characterized in detail the dynamics of maturation and the composition of the graft. Comparison of in vivo and in vitro differentiation will allow evaluation of the quality of cellular material for transplantation.

Overcoming Graft Rejection in Induced Pluripotent Stem Cell-Derived Inhibitory Interneurons for Drug-Resistant Epilepsy

Masterminding Hippocampal Circuits by Transplanting Human GABAergic Interneurons to Treat Temporal Lobe Epilepsy

Human cortical interneurons optimized for grafting specifically integrate, abort seizures, and display prolonged efficacy without over-inhibition

Transplantation of neurogenic-fusionogenic embryonic stem cells modified to overexpress GABA into a model of temporal lobe epilepsy: Promises and potential pitfalls.

Progress and Challenges of Cell Replacement Therapy for Neurodegenerative Diseases Based on Direct Neural Reprogramming

An update on intracerebral stem cell grafts

Advancing Parkinson's disease treatment: cell replacement therapy with neurons derived from pluripotent stem cells

Stem Cell Therapy and Immunological Rejection in Animal Models

Neural grafting for Parkinson's disease: challenges and prospects

Utility of Induced Pluripotent Stem Cells for the Study and Treatment of Genetic Diseases: Focus on Childhood Neurological Disorders

Cell therapy for Parkinson’s disease with induced pluripotent stem cells

Potential therapeutic applications of differentiated induced pluripotent stem cells (iPSCs) in the treatment of neurodegenerative diseases.

The fate of iPSCs-derived low immunogenic dopaminergic neuron precursors after transplantation into the striatum of rats with 6-OHDA-induced parkinsonism

Human induced pluripotent stem cell-derived MGE cell grafting after status epilepticus attenuates chronic epilepsy and comorbidities via synaptic integration

The Immunogenicity and Immune Tolerance of Pluripotent Stem Cell Derivatives

The Potential of Induced Pluripotent Stem Cells to Test Gene Therapy Approaches for Neuromuscular and Motor Neuron Disorders

Human pallial MGE-type GABAergic interneuron cell therapy for chronic focal epilepsy

Induced Pluripotent Stem Cells and Parkinson's Disease: Modelling and Treatment

Cell Transplantation for Spinal Cord Injury: Tumorigenicity of Induced Pluripotent Stem Cell-Derived Neural Stem/Progenitor Cells

Potential application of induced pluripotent stem cells in cell replacement therapy for parkinson's disease

Beneath the radar: immune-evasive cell sources for stroke therapy